You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
NameTranexamic Acid
Accession NumberDB00302  (APRD01270, EXPT00508)
TypeSmall Molecule
DescriptionAntifibrinolytic hemostatic used in severe hemorrhage. [PubChem]
Acide tranexamique
Acido tranexamico
Acidum tranexamicum
Tranexmic acid
Tranhexamic acid
trans-4-(Aminomethyl)cyclohexanecarboxylic acid
trans-4-aminomethylcyclohexane-1-carboxylic acid
trans-Tranexamic acid
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyklokaproninjection, solution100 mg/mLintravenousPharmacia And Upjohn Company Llc1986-12-30Not applicableUs
Cyklokapron 100 mg/mlsolution100 mgintravenousPfizer Canada Inc1995-12-31Not applicableCanada
Cyklokapron 500 mgtablet500 mgoralPfizer Canada Inc1995-12-31Not applicableCanada
Erfa-tranexamicsolution100 mgintravenousErfa Canada 2012 IncNot applicableNot applicableCanada
Gd-tranexamic Acidtablet500 mgoralGenmed A Division Of Pfizer Canada Inc2014-03-07Not applicableCanada
Gd-tranexamic Acidsolution100 mgintravenousGenmed A Division Of Pfizer Canada IncNot applicableNot applicableCanada
Lystedatablet650 mg/1oralFerring Pharmaceuticals Inc.2010-05-172016-10-13Us
Lystedatablet650.0 mgoralFerring IncNot applicableNot applicableCanada
Lystedatablet650 mg/1oralFerring Pharmaceuticals Inc.2010-05-17Not applicableUs
Tranexamic Acidtablet650 mg/1oralPrasco Laboratories2010-05-17Not applicableUs
Tranexamic Acidtablet650 mg/1oralPrasco Laboratories2010-05-17Not applicableUs
Tranexamic Acidtablet650 mg/1oralAmring Pharmaceuticals, Inc.2016-03-01Not applicableUs
Tranexamic Acid Injectionsolution100 mgintravenousOmega Laboratories Ltd2013-03-27Not applicableCanada
Tranexamic Acid Injectionsolution100 mgintravenousMethapharm IncNot applicableNot applicableCanada
Tranexamic Acid Injection BPsolution100 mgintravenousSandoz Canada Incorporated2002-10-29Not applicableCanada
Tranexamic Acid Injection BPsolution100 mgintravenousSterimax Inc2012-11-15Not applicableCanada
Tranexamic Acid Injection BPsolution100 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Tranexamic Acid Tabletstablet500 mgoralSterimax Inc2013-02-13Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tranexamic Acidtablet650 1/1oralGolden State Medical Supply, Inc.2014-08-20Not applicableUs
Tranexamic Acidinjection, solution1 g/10mLintravenousHeritage Pharmaceuticals Inc.2012-02-20Not applicableUs
Tranexamic Acidtablet, film coated650 mg/1oralActavis Pharma, Inc.2013-01-03Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousMylan Institutional LLC2011-11-29Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousX Gen Pharmaceuticals, Inc.2012-05-18Not applicableUs
Tranexamic Acidtablet650 1/1oralApotex Corp.2014-01-27Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousNexus Pharmaceuticals Inc2012-03-15Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousAkorn, Inc.2016-06-09Not applicableUs
Tranexamic Acidtablet, film coated650 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousX Gen Pharmaceuticals, Inc.2012-05-18Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousFresenius Kabi USA, LLC2012-04-20Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousAkorn, Inc.2015-03-09Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousAuro Medics Pharma Llc2016-01-14Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousACELLA PHARMACEUTICALS2014-02-11Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousMylan Institutional LLC2011-11-29Not applicableUs
Tranexamic Acidinjection, solution1 g/10mLintravenousHeritage Pharmaceuticals Inc.2014-08-13Not applicableUs
Tranexamic Acidinjection, solution100 mg/mLintravenousAmerican Regent, Inc.2011-11-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pure Whitenol Serumcream.05 mg/50mLtopicalSkin M.D. Korea2015-02-01Not applicableUs
International Brands
Cyclo-FNot Available
EspercilNot Available
FemstrualNot Available
RikavarinNot Available
TransaminNot Available
TranscamNot Available
TraxylNot Available
Brand mixturesNot Available
SaltsNot Available
CAS number1197-18-8
WeightAverage: 157.2102
Monoisotopic: 157.110278729
Chemical FormulaC8H15NO2
(1r,4r)-4-(aminomethyl)cyclohexane-1-carboxylic acid
NC[[email protected]]1CC[C@@H](CC1)C(O)=O
IndicationFor use in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. It can also be used for excessive bleeding in menstruation, surgery, or trauma cases.
Structured Indications
PharmacodynamicsTranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin. Tranexamic acid is a competitive inhibitor of plasminogen activation, and at much higher concentrations, a noncompetitive inhibitor of plasmin, i.e., actions similar to aminocaproic acid. Tranexamic acid is about 10 times more potent in vitro than aminocaproic acid. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. Tranexamic acid in a concentration of 1 mg per mL does not aggregate platelets in vitro. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
Mechanism of actionTranexamic acid competitively inhibits activation of plasminogen (via binding to the kringle domain), thereby reducing conversion of plasminogen to plasmin (fibrinolysin), an enzyme that degrades fibrin clots, fibrinogen, and other plasma proteins, including the procoagulant factors V and VIII. Tranexamic acid also directly inhibits plasmin activity, but higher doses are required than are needed to reduce plasmin formation.
TargetKindPharmacological actionActionsOrganismUniProt ID
HumanP00747 details
Related Articles
AbsorptionAbsorption of tranexamic acid after oral administration in humans represents approximately 30 to 50% of the ingested dose and bioavailability is not affected by food intake.
Volume of distribution
  • 9 to 12 L
Protein bindingThe plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen (does not bind serum albumin).

Only a small fraction of the drug is metabolized (less than 5%).

Route of eliminationUrinary excretion is the main route of elimination via glomerular filtration.
Half lifeBiological half-life in the joint fluid is about 3 hours.
  • 110 – 116 mL/min
ToxicityOral LD50 in mice is >10 gm/kg. Symptoms of overdosage may be nausea, vomiting, orthostatic symptoms and/or hypotension.
Affected organisms
  • Humans and other mammals
PathwayCategorySMPDB ID
Tranexamic Acid Action PathwayDrug actionSMP00287
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Drug Interactions
Factor IX Complex (Human)Tranexamic Acid may increase the thrombogenic activities of Factor IX Complex (Human).
Fibrinogen Concentrate (Human)The risk or severity of adverse effects can be increased when Tranexamic Acid is combined with Fibrinogen Concentrate (Human).
TretinoinTretinoin may increase the thrombogenic activities of Tranexamic Acid.
Food InteractionsNot Available
Synthesis Reference

Noa Zerangue, Bernd Jandeleit, Yunxiao Li, “Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use.” U.S. Patent US20070027210, issued February 01, 2007.

General ReferencesNot Available
External Links
ATC CodesB02AA02
AHFS Codes
  • 20:28.16
PDB Entries
FDA labelNot Available
MSDSDownload (63.5 KB)
Predicted ADMET features
Human Intestinal Absorption+0.9538
Blood Brain Barrier+0.8672
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.7572
P-glycoprotein inhibitor INon-inhibitor0.9915
P-glycoprotein inhibitor IINon-inhibitor0.8475
Renal organic cation transporterNon-inhibitor0.7446
CYP450 2C9 substrateNon-substrate0.8862
CYP450 2D6 substrateNon-substrate0.7898
CYP450 3A4 substrateNon-substrate0.829
CYP450 1A2 substrateNon-inhibitor0.9504
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9577
CYP450 2C19 inhibitorNon-inhibitor0.9452
CYP450 3A4 inhibitorNon-inhibitor0.9313
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9698
Ames testNon AMES toxic0.8916
BiodegradationReady biodegradable0.6921
Rat acute toxicity1.0517 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8797
hERG inhibition (predictor II)Non-inhibitor0.9156
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
  • Pharmacia and upjohn co
  • Ferring pharmaceuticals as
Dosage forms
Solutionintravenous100 mg
Tabletoral500 mg
Tabletoral650 mg/1
Tabletoral650.0 mg
Creamtopical.05 mg/50mL
Injection, solutionintravenous1 g/10mL
Injection, solutionintravenous100 mg/mL
Tabletoral650 1/1
Tablet, film coatedoral650 mg/1
Unit descriptionCostUnit
Cyklokapron 100 mg/ml ampul8.8USD ml
Tranexamic acid powder1.97USD g
Cyklokapron 500 mg Tablet1.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7947739 No2005-03-042025-03-04Us
US8022106 No2005-03-042025-03-04Us
US8273795 No2005-03-042025-03-04Us
US8487005 No2005-03-042025-03-04Us
US8791160 No2005-03-042025-03-04Us
US8809394 No2005-03-042025-03-04Us
US8957113 No2005-03-042025-03-04Us
US9060939 No2005-03-042025-03-04Us
Experimental Properties
melting point>300 °CPhysProp
water solubility1.67E+005 mg/LMERCK INDEX (1996)
logP0.3Not Available
Predicted Properties
Water Solubility18.2 mg/mLALOGPS
pKa (Strongest Acidic)4.56ChemAxon
pKa (Strongest Basic)10.22ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity41.9 m3·mol-1ChemAxon
Polarizability17.28 Å3ChemAxon
Number of Rings1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Mass Spec (NIST)Not Available
SpectraNot Available
DescriptionThis compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acids
Direct ParentCarboxylic acids
Alternative Parents
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Aliphatic homomonocyclic compound
Molecular FrameworkAliphatic homomonocyclic compounds
External DescriptorsNot Available


Pharmacological action
General Function:
Serine-type peptidase activity
Specific Function:
Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin ...
Gene Name:
Uniprot ID:
Molecular Weight:
90568.415 Da
  1. Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. [PubMed:10400410 ]
  2. Marti DN, Schaller J, Llinas M: Solution structure and dynamics of the plasminogen kringle 2-AMCHA complex: 3(1)-helix in homologous domains. Biochemistry. 1999 Nov 30;38(48):15741-55. [PubMed:10625440 ]
  3. Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K: Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth. 1999 Oct;83(4):596-601. [PubMed:10673876 ]
  4. Bangert K, Thorsen S: Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis. Thromb Haemost. 2000 Aug;84(2):299-306. [PubMed:10959704 ]
  5. Hanson AJ, Quinn MT: Effect of fibrin sealant composition on human neutrophil chemotaxis. J Biomed Mater Res. 2002 Sep 5;61(3):474-81. [PubMed:12115473 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]


Pharmacological action
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
Uniprot ID:
Molecular Weight:
81782.77 Da
  1. Dieck ST, Heuer H, Ehrchen J, Otto C, Bauer K: The peptide transporter PepT2 is expressed in rat brain and mediates the accumulation of the fluorescent dipeptide derivative beta-Ala-Lys-Nepsilon-AMCA in astrocytes. Glia. 1999 Jan;25(1):10-20. [PubMed:9888294 ]
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on October 22, 2016 02:35